Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pioglitazone

- PMLiVE

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Body cites uncertain evidence and unlikely value for the NHS

- PMLiVE

AZ and Lilly start BACE inhibitor trial in Alzheimer’s

Early trials show promise for the BACE inhibitor AZD3293

- PMLiVE

Takeda enlists GE’s aid to tackle liver fibrosis epidemic

Non-alcoholic liver disease has doubled in the last 20 years

- PMLiVE

Takeda launches mobile app for heartburn patients

Food4GERD app includes symptom tracker and ingredient check functions

- PMLiVE

US judge cuts billions from Takeda/Lilly Actos payment

Court rules that companies must now pay damages of $36.8m rather than $9bn

- PMLiVE

Takeda’s obesity drug Contrave launches in US

Clears cardiovascular safety hurdle to be third new weight-loss drug in recent months

- PMLiVE

Takeda appoints head of vaccines development

John Boslego will succeed Ralf Clemens

- PMLiVE

Takeda opens new UK office in High Wycombe

Hopes move to larger premises will help expand business

- PMLiVE

Takeda loses in lawsuit claiming cancer link to Actos

Ordered to compensate woman who claims drug gave her bladder cancer

- PMLiVE

AZ and Lilly set up BACE camp for Alzheimer’s

Lilly will pay AZ up to $500m in development and regulatory costs

- PMLiVE

Second time lucky for Takeda’s obesity drug

FDA approves Contrave three years after initial rejection

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links